Uneven growth rate in the beginning (first year or two) but smoothing out over time as more and more customers added to the rolls. There will come a time when BTM will become the treatment standard, and quite honestly, I don't see that taking five years, given the dramatic improvements in shelf life, ease of storage, ease of use in the operating room, reduction in infection rates, lower costs, faster recoveries, and improved outcomes. All this will become known to every surgeon working in the field very quickly indeed.
Alan Kohler/Paul Brennan Interview - 19.10.2017, page-43
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.32 |
Change
-0.020(0.85%) |
Mkt cap ! $1.602B | |||
| Open | High | Low | Value | Volume |
| $2.35 | $2.37 | $2.30 | $2.354M | 1.012M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 11423 | $2.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.33 | 8018 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |